BioMarin [BMRN] vs Royalty Pharma plc [RPRX] Detailed Stock Comparison

BioMarin

NASDAQ
Loading...

Royalty Pharma plc

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: BioMarin wins in 9 metrics, Royalty Pharma plc wins in 9 metrics, with 0 ties. Both stocks appear equally matched on key metrics.

View Metrics Details

Vital Metrics Comparison

MetricBioMarinRoyalty Pharma plcBetter
P/E Ratio (TTM)16.3515.75Royalty Pharma plc
Price-to-Book Ratio1.772.46BioMarin
Debt-to-Equity Ratio10.0284.43BioMarin
PEG Ratio0.13-0.23Royalty Pharma plc
EV/EBITDA10.2819.10BioMarin
Profit Margin (TTM)21.45%44.28%Royalty Pharma plc
Operating Margin (TTM)33.55%38.85%Royalty Pharma plc
EBITDA Margin (TTM)33.55%38.85%Royalty Pharma plc
Return on Equity11.62%17.29%Royalty Pharma plc
Return on Assets (TTM)7.50%6.49%BioMarin
Free Cash Flow (TTM)$475.42M$2.77BRoyalty Pharma plc
Dividend YieldN/A3.03%N/A
1-Year Return-20.95%28.94%Royalty Pharma plc
Price-to-Sales Ratio (TTM)3.479.12BioMarin
Enterprise Value$9.82B$26.13BRoyalty Pharma plc
EV/Revenue Ratio3.2011.33BioMarin
Gross Profit Margin (TTM)81.82%N/AN/A
Revenue per Share (TTM)$16$5BioMarin
Earnings per Share (Diluted)$3.39$2.29BioMarin
Beta (Stock Volatility)0.330.59BioMarin
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

BioMarin vs Royalty Pharma plc Stock Performance Analysis

Loading Price Chart...

BioMarin
Royalty Pharma plc
BioMarin Stock Overview | Royalty Pharma plc Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
BioMarin-1.64%2.94%-1.37%-3.14%-6.00%-16.36%
Royalty Pharma plc-0.08%2.50%0.92%1.52%16.44%40.09%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
BioMarin-20.95%-36.26%-29.83%-48.91%153.12%631.71%
Royalty Pharma plc28.94%-12.75%-13.59%-26.27%-26.27%-26.27%

News Based Sentiment: BioMarin vs Royalty Pharma plc

BioMarin

News based Sentiment: MIXED

October was a month of contrasts for BioMarin, with positive developments like the Inozyme Pharma acquisition and strong analyst ratings balanced by weak momentum and a discount to fair value. This mixed picture suggests a complex investment story with both opportunities and risks, making it a significant month for the company's trajectory.

View BioMarin News Sentiment Analysis

Royalty Pharma plc

News based Sentiment: MIXED

Royalty Pharma experienced a month of mixed signals, with positive analyst upgrades and insider buying countered by a slight stock decline and a less favorable Halal stock rating. The company's strong financial performance and inclusion in an inflation-focused ETF suggest continued potential, but investors should weigh the conflicting indicators.

View Royalty Pharma plc News Sentiment Analysis

Performance & Financial Health Analysis: BioMarin vs Royalty Pharma plc

MetricBMRNRPRX
Market Information
Market Cap i$10.64B$21.04B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i2,085,8404,887,150
90 Day Avg. Volume i2,017,8735,137,523
Last Close$54.70$36.10
52 Week Range$52.48 - $73.51$24.05 - $38.00
% from 52W High-25.59%-5.00%
All-Time High$151.75 (Jul 20, 2015)$56.50 (Jun 15, 2020)
% from All-Time High-63.95%-36.11%
Growth Metrics
Quarterly Revenue Growth0.16%0.08%
Quarterly Earnings Growth1.24%-0.70%
Financial Health
Profit Margin (TTM) i0.21%0.44%
Operating Margin (TTM) i0.34%0.39%
Return on Equity (TTM) i0.12%0.17%
Debt to Equity (MRQ) i10.0284.43
Cash & Liquidity
Book Value per Share (MRQ)$31.39$14.68
Cash per Share (MRQ)$7.46$1.49
Operating Cash Flow (TTM) i$766.77M$2.41B
Levered Free Cash Flow (TTM) i$503.09M$-746,665,024
Dividends
Last 12-Month Dividend Yield iN/A3.03%
Last 12-Month Dividend iN/A$1.08

Valuation & Enterprise Metrics Analysis: BioMarin vs Royalty Pharma plc

MetricBMRNRPRX
Price Ratios
P/E Ratio (TTM) i16.3515.75
Forward P/E i18.548.22
PEG Ratio i0.13-0.23
Price to Sales (TTM) i3.479.12
Price to Book (MRQ) i1.772.46
Market Capitalization
Market Capitalization i$10.64B$21.04B
Enterprise Value i$9.82B$26.13B
Enterprise Value Metrics
Enterprise to Revenue i3.2011.33
Enterprise to EBITDA i10.2819.10
Risk & Other Metrics
Beta i0.330.59
Book Value per Share (MRQ) i$31.39$14.68

Financial Statements Comparison: BioMarin vs Royalty Pharma plc

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)BMRNRPRX
Revenue/Sales i$825.41M$578.67M
Cost of Goods Sold i$150.09MN/A
Gross Profit i$675.32MN/A
Research & Development i$161.31M$300.50M
Operating Income (EBIT) i$276.87M$209.80M
EBITDA i$319.11M$219.28M
Pre-Tax Income i$297.87M$90.64M
Income Tax i$57.34M$0
Net Income (Profit) i$240.53M$90.64M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)BMRNRPRX
Cash & Equivalents i$1.05B$1.09B
Total Current Assets i$3.47B$1.84B
Total Current Liabilities i$628.21M$1.18B
Long-Term Debt i$595.65M$6.62B
Total Shareholders Equity i$5.79B$9.79B
Retained Earnings i$-9.01M$2.48B
Property, Plant & Equipment iN/AN/A

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)BMRNRPRX
Operating Cash Flow i$182.82M$1.28B
Capital Expenditures i$-16.77MN/A
Free Cash Flow i$157.63M$596.08M
Debt Repayment iN/AN/A
Common Stock Repurchase iN/A$-708.78M

Short Interest & Institutional Ownership Analysis

MetricBMRNRPRX
Shares Short i7.31M21.28M
Short Ratio i4.155.37
Short % of Float i0.05%0.05%
Average Daily Volume (10 Day) i2,085,8404,887,150
Average Daily Volume (90 Day) i2,017,8735,137,523
Shares Outstanding i190.76M445.99M
Float Shares i178.10M379.85M
% Held by Insiders i0.01%0.09%
% Held by Institutions i0.99%0.83%

Dividend Analysis & Yield Comparison: BioMarin vs Royalty Pharma plc

MetricBMRNRPRX
Last 12-Month Dividend iN/A$1.08
Last 12-Month Dividend Yield iN/A3.03%
3-Year Avg Annual Dividend iN/A$0.89
3-Year Avg Dividend Yield iN/A0.64%
3-Year Total Dividends iN/A$2.68
Ex-Dividend DateN/AAug 15, 2025